NASDAQHealth CareDiagnostics & ResearchSnapshot 2026-07-23
Reading OPK? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a speculative growth opportunity. The company is currently loss-making, and while it has stable management, its recent financial performance has been neutral, indicating uncertainty in its growth trajectory.
The market appears to have priced in a low level of fragility, suggesting that expectations are somewhat justified given the company's current valuation. OPK is seen as cheap compared to its peers, but there is a significant expectations gap that could impact future performance.
Management has set ambitious revenue targets for 2026, but recent results show limited progress towards these goals. The company is facing challenges in improving operating income and gross profit, which may hinder its ability to meet future expectations.
The thesis hinges on the performance of sector bellwethers like TMO, DHR, and IDXX. If these companies continue to perform well, it could provide a tailwind for OPK. Conversely, any negative guidance from these peers could lead to a decline in OPK's prospects.
Over the next 1 to 3 years, OPK's performance will depend on its ability to improve financial metrics and the overall health of the healthcare sector. Not investment advice.
The most important moves since the prior daily snapshot.
risk label changed from 'elevated' to 'moderate'.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Changes to revenue guidance may show if OPKO can reach its $530M-$560M target.
Confirms one read:Management raises the revenue guidance for 2026 above $530M.
Confirms the other:Management lowers the revenue guidance for 2026 below $530M.
Why it matters: A gross profit above $50M would signal a positive shift in OPKO's financial health.
Confirms:If gross profit is over $50M, it shows recovery from recent drops.
Disproves:If gross profit is below $50M, it shows ongoing trouble making money.
Why it matters: Earnings reports can explain management's view and how they meet their goals.
Confirms one read:Earnings report shows better revenue guidance.
Confirms the other:Earnings report shows lower revenue guidance.
Why it matters: This revenue figure is crucial to stay on track for the annual guidance of $530M-$560M.
Confirms:Q2 revenue reported at $140M or more would indicate progress toward annual goals.
Disproves:If Q2 revenue is below $140M, it shows trouble meeting annual goals.
Why it matters: If healthcare sector revenue growth speeds up, it may help OPKO's performance. This could signal a better environment for OPKO.
Confirms:Healthcare sector revenue growth exceeds 10% year over year.
Disproves:Healthcare sector revenue growth remains below 10% year over year.
Why it matters: Good results would help OPKO's COVID-19 treatment plan. This would make investors more confident.
Confirms:A press release says the MDX2301 trial was safe and tolerable.
Disproves:News that the trial did not meet its primary endpoint or faced significant delays.
Why it matters: Filing an IND would show progress in OPKO's work with Entera Bio and market entry.
Confirms:An announcement says the IND application has been sent to the FDA.
Disproves:News that the IND application will be delayed or not filed as planned.
Why it matters: Higher operating income means OPKO is controlling costs well. It shows the company is running smoothly.
Confirms:Operating income improves to less than -$51M in Q2 2026.
Disproves:Operating income worsens, remaining worse than -$51M in Q2 2026.
